The assessment of the toxicological properties of contemporary and novel smokeless tobacco products (STP) on the US market can be challenging. The responses of the extracts of such products in common in vitro assays are generally marginal, if indeed, a positive response is obtained at all. Levels of the so-called GothiaTek analyses are often close to, if not below the levels found in Swedish snus. Therefore, any assessment of the toxicological properties of such STP requires a more complete knowledge of the product composition than can be obtained from routine analyses alone. One such analytical scheme was recently reported by Goodpaster et. al. [J. Agric. Food Chem., 2011, 59 (6), pp 2745-2751]. Goodpaster used several GC-MS techniques to analyze semivolatiles and nicotine in novel STP; however, he only found a few of the compounds present in the samples. Moreover, he incorrectly used the Henderson-Hasselbalch equation to estimate the percent of nicotine in the products that was not protonated, and his assessments of the toxicological properties of the analytes he found were less than correct. We will present the results of our detailed GC-MS analyses of novel STP products including some studied by Goodpaster using techniques we reported at the CORESTA Smoke Science and Product Technology meeting in 2009 (SSPT 11). Our results showed that Goodpaster missed compounds of potential toxicological interest. We will also show why the Henderson-Hasselbalch equation is not satisfactory for use with novel STP, and we will provide a critique of Goodpaster's toxicological assessments of the ingredients he found in them.